The Technical Analyst
Marrone Bio Innovations [MBII]
Exchange: NASDAQ Sector: Basic Materials Industry: Agricultural Inputs
Marrone Bio Innovations Price, Forecast, Insider, Ratings, Fundamentals & Signals
-20.19% $0.798
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-08-03 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.82 | sector: PE -48.27 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -6.82 | industry: PE -5.53 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.721 - 0.875 ( +/- 9.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-12 | Vasavada Amit | Buy | 129 184 | Common Stock |
| 2022-07-12 | Vasavada Amit | Sell | 285 892 | Common Stock |
| 2022-07-12 | Vasavada Amit | Sell | 129 184 | Restricted Stock Units |
| 2022-07-12 | Vasavada Amit | Sell | 185 455 | Stock Option (Right to Buy) |
| 2022-07-12 | Vasavada Amit | Sell | 20 000 | Stock Option (Right to Buy |
| INSIDER POWER |
|---|
| -95.83 |
| Last 98 transactions |
| Buy: 7 643 681 | Sell: 84 615 046 |
Forecast:
01:40 - $1.155
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.798 (-20.19% ) |
| Volume | 7.39 mill |
| Avg. Vol. | 0.873 mill |
| % of Avg. Vol | 846.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MBII
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MBII
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
Latest Press Releases
2022-07-12 16:43:00 - Press Release
Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating A Global Leader In Sustainable Agricultural Solutions
Rosario, argentina--(business wire)--bioceres crop solutions completes merger with madrone bio, creating a global leader in sustainable agricultural solutions
2022-07-11 08:30:00 - Press Release
Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement With Bioceres Crop Solutions Corp.
Raleigh, n.c., july 11, 2022 (globe newswire) -- marrone bio innovations, inc. (nasdaq: mbii) (mbi) announced that during a special shareholder meeting held on july 8, 2022, its shareholders approved a proposal to adopt the previously announced agreement and plan of merger (merger agreement), dated as of march 16, 2022, by and among bioceres crop solutions corp. (biox), bcs merger sub, inc., and mbi, pursuant to which mbi will be acquired by biox. at the special meeting, mbi's stockholders approved the adoption of the merger agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by the merger agreement...
2022-05-11 16:01:00 - Press Release
Marrone Bio Innovations, Inc. Reports First-quarter 2022 Financial Results
Raleigh, n.c., may 11, 2022 (globe newswire) -- marrone bio innovations, inc. (nasdaq: mbii), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended march 31, 2022. key results include:
2022-05-04 16:05:00 - Press Release
Marrone Bio Investor Alert - Kuznicki Law Pllc Investigates Proposed Sale Of Marrone Bio Innovations, Inc. - Mbii
Cedarhurst, n.y.--(business wire)--kuznicki law pllc is investigating the proposed sale of marrone bio innovations, inc. (nasdaqcm: mbii) to bioceres crop solutions corp. (nasdaqgs: biox). under the terms of the proposed transaction, shareholders of marrone will receive only 0.088 shares of bioceres for each share of marrone that they own. if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or visit https://kclasslaw.com/cases/ma/nasdaqcm-mbii/ to learn more. kuznicki law pllc is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship...
2022-04-27 16:16:00 - Press Release
Marrone Bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Marrone Bio Innovations, Inc. - Mbii
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of marrone bio innovations, inc. (nasdaqcm: mbii) to bioceres crop solutions corp. (nasdaqgs: biox). under the terms of the proposed transaction, shareholders of marrone will receive only 0.088 shares of bioceres for each share of marrone that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the company. if you believe that this transaction undervalues the company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call ksf managing partner lewis s...
Latest News
2022-05-17 14:18:04 - Zacks Investment Research
Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1
Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.
2022-05-11 20:01:06 - Seeking Alpha
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q1 2022 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. (NASDAQ:MBII ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen – Senior Vice President International Sales Kamal El Mernissi – Senior Director of Product & Marketing Conference Call Participants Dmitry Silversteyn – Water Tower Research Operator Good afternoon ladies and gentlemen, and welcome to the First Quarter 2022 Earnings conference call. At this time all participants are in a listen-only mode.
2022-05-11 18:49:13 - Zacks Investment Research
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-28 21:49:08 - Zacks Investment Research
Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-03-28 19:48:02 - Seeking Alpha
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript
2022-03-22 10:22:56 - PennyStocks
Best Penny Stocks To Buy? 4 Agriculture & Farmings Stocks To Watch
Farming & Agriculture Penny Stocks To Watch Right Now. The post Best Penny Stocks To Buy?
2022-03-17 14:33:42 - InvestorPlace
Why Is Marrone Bio Innovations (MBII) Stock Up Today?
Today, a big merger announcement has prompted investors to pile into Marrone Bio Innovations and MBII stock, as this stock surges 50%. The post Why Is Marrone Bio Innovations (MBII) Stock Up Today?
2022-03-08 08:00:00 - GlobeNewsWire
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 at 4:30 p.m. Eastern Time
RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2021, after market close on Monday, March 28, 2022.
2022-01-10 11:30:14 - Zacks Investment Research
Marrone (MBII) Expands the Existing Inventory Line of Credit
Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.
2021-11-25 05:51:02 - Seeking Alpha
Switching From Israel Chemicals To Mosaic
